Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

  • End date
    Sep 1, 2026
  • participants needed
  • sponsor
    Millennium Pharmaceuticals, Inc.
Updated on 16 May 2021
growth factor
maintenance therapy
cell transplantation
bone marrow procedure
neutrophil count


The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.


The drug being tested in this study is called ixazomib. Ixazomib is being tested to slow disease progression and improve overall survival in Chinese participants who have newly diagnosed multiple myeloma (NDMM) who have had a major positive response to initial therapy and have not undergone stem cell transplantation (SCT). This study will look at the effect of ixazomib has on the length of time that participants are free of disease progression and their overall survival. After the implementation of Amendment 8, participants who received placebo-matching capsules before unblinding and have not yet experienced disease progression will cross over to receive ixazomib.

The study will enroll approximately 30 patients. Participants will be assigned to a single treatment group


All participants will be asked to take one capsule on Days 1, 8, and 15 of every 28-day cycle, for up to 26 cycles or until documented PD or intolerable toxicity, whichever occurs first.

This multi-center trial will be conducted in China. The overall time to participate in this study is until a total of approximately up to 67 months. Participants will make multiple visits to the clinic, and every 4 weeks until the next line of therapy begins for a follow-up assessment.

Condition Multiple Myeloma, Lymphoproliferative Disorder, Lymphoproliferative disorders, multiple myeloma (mm)
Treatment Ixazomib, Ixazomib Placebo
Clinical Study IdentifierNCT03748953
SponsorMillennium Pharmaceuticals, Inc.
Last Modified on16 May 2021


Yes No Not Sure

Inclusion Criteria

Adult male or female participants aged 18 years or older with a confirmed diagnosis of symptomatic NDMM according to standard criteria
Has completed 6 to 12 months ( 2 weeks) of initial therapy, during which the participant was treated to best response, defined as the best response maintained for 2 cycles after the M-protein nadir is reached
Has documented major response [partial response (PR), very good partial response (VGPR), complete response (CR)] according to the international myeloma working group (IMWG) uniform response criteria, version 2011, after this initial therapy
Female participants who
Are postmenopausal for at least 1 year before the screening visit, OR Are
surgically sterile, OR If they are of childbearing potential, agree to
practice 2 effective methods of contraception, at the same time, from the time
of signing the informed consent through 90 days after the last dose of study
drug, or Agree to practice true abstinence, when this is in line with the
preferred and usual lifestyle of the participant. (Periodic abstinence (eg
calendar, ovulation,symptothermal, postovulation methods] and withdrawal are
not acceptablemethods of contraception.)
Male participants, even if surgically sterilized (ie, status postvasectomy)
Agree to practice effective barrier contraception during the entire study
Treatment period and through 90 days after the last dose of study drug, or
Agree to practice true abstinence, when this is in line with the preferred and
usual lifestyle of the participant. (Periodic abstinence [eg, calendar
ovulation, symptothermal, postovulation methods for the female partner] and
withdrawal are not acceptable methods of contraception.)
\. Voluntary written consent must be given before performance of any study-
related procedure not part of standard medical care, with the understanding
that consent may be withdrawn by the participant at any time without prejudice
to future medical care
\. Has availability of complete documentation for
Details of initial disease state, initial therapy, and response
Cytogenetic assessment at diagnosis (cytogenetic assessment performed after diagnosis must be approved by a Millennium project clinician or designee)
ISS staging at diagnosis (requiring beta 2-microglobulin and serum albumin results)
Has eastern cooperative oncology group performance status of 0 to 2
Suitable venous access for the study-required blood sampling and consent for the specific amounts that will be taken
Participant is willing and able to adhere to the study visit schedule and other protocol requirements including blood sampling and bone marrow aspiration
Participants must meet the following clinical laboratory criteria at study entry
Absolute neutrophil count (ANC) 1,000/mm^3 without growth factor support and platelet count 75,000/mm^3. Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before randomization
Total bilirubin1.5 _the upper limit of the normal range (ULN). 3. Alanine aminotransferase and aspartate aminotransferase3_ ULN. 4. Calculated creatinine clearance 30 mL/min (using the Cockroft-Gault equation

Exclusion Criteria

Has multiple myeloma that has relapsed after, or was not responsive to, initial therapy
Had prior stem-cell transplantation (SCT)
Has radiotherapy within 14 days before randomization
Had diagnosed or treated for another malignancy within 5 years before randomization or previously diagnosed with another malignancy with evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period
Has major surgery within 14 days before randomization
Has central nervous system involvement
Infection requiring IV antibiotic therapy or other serious infection within 14 days before randomization
Has diagnosis of waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use of St. John's wort within 14 days before randomization
Ongoing or active infection, known human immunodeficiency virus positive, active hepatitis B or C infection
Has comorbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens (eg, peripheral neuropathy (PN) that is Grade 1 with pain or Grade 2 or higher of any cause)
Psychiatric illness/social situation that would limit compliance with study requirements
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or GI procedure that could interfere with the oral absorption or tolerance of treatment
Treatment with any investigational products within 30 days before randomization
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note